Home›Earnings›Previews›Novo Nordisk CEO says investors underestimate drug pro…

Novo Nordisk CEO says investors underestimate drug prospects

Reported · Written up by our desk · Previews

The New York Times Business reports that Novo Nordisk chief executive Mike Doustdar said the company’s investors remain too cautious about the future of its therapies.

The outlet frames Doustdar’s comments as coming during an ongoing corporate turnaround, noting he is about a year into the effort.

According to the report, Doustdar argues that investors are still failing to fully appreciate the promise of Novo Nordisk’s drugs.

More like this

Sources